Butterfly Network Pursues Ultrasound Brain-Computer Interfaces with Bridge Neurotech

Butterfly Network, the maker of the handheld point-of-care ultrasound platform, will pursue ultrasound-based brain-computer interfaces through a partnership with the newly formed company Bridge Neurotech, MassDevice reports.

The collaboration pairs an established medical imaging hardware developer with a newcomer to the neurotechnology field. The stated goal is to apply ultrasound technology to brain-computer interfaces (BCIs), systems that record neural signals and translate them into control of external devices.

Why ultrasound for a brain-computer interface?

Butterfly Network has built its business on miniaturized ultrasound: semiconductor-based probes that clinicians carry in a pocket and connect to a smartphone. Extending that technology toward the brain raises a technical question the field has not yet settled — whether ultrasound can serve as a recording and stimulation modality for BCI applications at all.

Most implantable BCI programs to date have relied on intracranial electrode arrays, including ECoG (electrocorticography, recordings from electrodes placed directly on the cortical surface) and depth-electrode configurations. An ultrasound approach would represent a departure from that hardware lineage. The announcement does not specify which neural signal ultrasound would capture, the anatomical target, or whether the work involves human implantation, animal models, or preclinical bench development.

What the partnership does and does not establish

The MassDevice report confirms the direction of the collaboration, not its results. No device has received FDA clearance for an ultrasound-based brain-computer interface, and readers in clinical neurophysiology settings should treat any such system as investigational until trial data or regulatory submissions appear.

Bridge Neurotech is described as a newcomer, and the pairing suggests Butterfly Network sees its core ultrasound-on-chip engineering as transferable to neural applications. For monitoring-unit and reading-room audiences, the practical near-term implications are limited: nothing in the announcement changes current scalp EEG, ECoG, or EMG practice.

What to watch next

The milestones that would matter for this space include first-in-human feasibility data, any FDA investigational device exemption filing, and clarity on whether the platform targets neural recording, stimulation, or both. Until those appear, the partnership stands as an early signal that ultrasound vendors are moving toward the cortical interface market.

By Priya Raman